Sign in with Google. Opens in new tab
bullish
Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy
490 Views22 Oct 2020 08:00
This article analyzed China’s revolutionary volume-based purchasing policy, its impact on domestic healthcare companies and related investment opportunities resulting from such policy.
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Santos Ltd (STO AU): FIRB Approval For XRG's Tilt Will Be No Pushover
- Gold Miners ETF (GDX US): BIG Impact of Benchmark Change
- SET50 Index Rebalance: Four Changes in Two Weeks; DELTA Capping Too
- Nakano Refrigerators (6411 JP): Marunouchi Capital’s JPY7,900 Tender Offer
- Shin Kong (2888 TT)/Taishin (2887 TT) - Short Timer, FX Risk, Index Flows - Time To Buy Vs Peers
Top Unpaywalled Insights
More »- Overview #27 – The Big Beautiful Tragi-Comedy Continues
- HK Connect SOUTHBOUND Flows (To 13 June 2025); Volumes Up, TECH Down, HEALTHCARE Bought Big
- [IO Technicals 2025/24] Downward Momentum Lingers
- China A-Share Consumer Staples: An Analysis of the Opportunities Ahead
- Bearishness Persist in Soybeans Despite Rebound Hopes
Discussions
(Paid Plans Only)
- Tigermed (300347.CN/03347.HK) - Q3 Performance Recovered with Optimistic Future Development05 Nov 2020
- Jiangsu Hengrui Medicine (600276 CH) - Q3 Performance Improved with Promising Innovative Pipeline28 Oct 2020
- China Healthcare Weekly (Oct.23)26 Oct 2020
- Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy22 Oct 2020
- A Different Angle - Simcere Pharmaceutical VS Everest Medicines (01952.HK)11 Oct 2020
- Betta Pharmaceuticals (300558.SZ) - The Harvest Season Is Coming07 Oct 2020
- Autonomous Driving- The Tesla Delusion05 Apr 2018
x